Vowst's FDA approval is a boon for the prevention of recurrent Clostridioides difficile infection

被引：1

作者：

Anand, Ayush ^{[1
,11
]}

Shaikh, Nameera Parveen ^{[7
,11
]}

Aggarwal, Yash ^{[3
,11
]}

Fatima, Umaima ^{[4
,11
]}

Chapagain, Sanskriti ^{[2
,11
]}

Chidurala, Rahul ^{[6
,11
]}

Vaghela, Jenish ^{[5
]}

Surana, Arihant ^{[8
]}

Parikh, Charmy ^{[9
]}

Patel, Raj H. ^{[10
]}

机构：

[1] BP Koirala Inst Hlth Sci, Dharan 56700, Nepal

[2] Devdaha Med Coll & Res Inst, Rupandehi, Nepal

[3] Govt Inst Med Sci, Greater Noida, India

[4] Shadan Inst Med Sci, Hyderabad, Telangana, India

[5] BJ Med Coll, Ahmadabad, Gujarat, India

[6] Sri Ramachandra Inst Higher Educ & Res, Chennai, Tamil Nadu, India

[7] Batumi Shota Rustaveli State Univ, Batumi, Georgia

[8] St Vincent Hosp, Dept Internal Med, Worcester, MA USA

[9] Carle BroMenn Med Ctr, Dept Internal Med, Normal, IL USA

[10] St Mary Hosp, Dept Internal Med, Langhorne, PA USA

[11] Global Consortium Med Educ & Res, Pune, India

来源：

ANNALS OF MEDICINE AND SURGERY | 2023年 / 85卷 / 12期

关键词：

THERAPY; SOCIETY; SER-109; UPDATE;

D O I：

10.1097/MS9.0000000000001410

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：5852 / 5854

页数：3

共 50 条

[1] Advancing therapeutics for recurrent clostridioides difficile infections: an overview of vowst's FDA approval and implications
Jain, Nityanand
Umar, Tungki Pratama
Fahner, Anne-Fleur
Gibietis, Valdis
GUT MICROBES, 2023, 15 (01)
[2] SER-109 (VOWST™): A Review in the Prevention of Recurrent Clostridioides difficile Infection
Blair, Hannah A.
DRUGS, 2024, 84 (03) : 257 - 274
[3] SER-109 (VOWST™): A Review in the Prevention of Recurrent Clostridioides difficile Infection
Hannah A. Blair
Drugs, 2024, 84 : 329 - 336
[4] Fecal microbiota spores, live-brpk (VOWST™/VOS) for prevention of recurrent Clostridioides difficile infection
Berry, Parul
Khanna, Sahil
FUTURE MICROBIOLOGY, 2024, 19 (18) : 1519 - 1528
[5] Prevention and treatment of recurrent Clostridioides difficile infection
Shin, Jae Hyun
Warren, Cirle A.
CURRENT OPINION IN INFECTIOUS DISEASES, 2019, 32 (05) : 482 - 489
[6] Recurrent Clostridioides difficile infection: Recognition, management, prevention
Tsigrelis, Constantine
CLEVELAND CLINIC JOURNAL OF MEDICINE, 2020, 87 (06) : 347 - 359
[7] Live Biotherapeutic Products for the Prevention of Recurrent Clostridioides difficile Infection
Pettit, Natasha N.
Shaeer, Kristy M.
Chahine, Elias B.
ANNALS OF PHARMACOTHERAPY, 2024, 58 (12) : 1204 - 1217
[8] Oral Vancomycin as Secondary Prophylaxis for Prevention of Recurrent Clostridioides difficile Infection
Chang, Leslie L.
Allegretti, Jessica
Skinner, Andrew M.
Dubberke, Erik R.
NEW ENGLAND JOURNAL OF MEDICINE, 2023, 388 (07): : 654 - 656
[9] Bezlotoxumab for Prevention of Recurrent Clostridioides difficile Infection With a Focus on Immunocompromised Patients
Askar, Sally F.
Kenney, Rachel M.
Tariq, Zain
Conner, Ruth
Williams, Jonathan
Ramesh, Mayur
Alangaden, George J.
JOURNAL OF PHARMACY PRACTICE, 2023, 36 (03) : 584 - 587
[10] Prevention of recurrent Clostridioides difficile infection: A systematic review of randomized controlled trials
Madoff, Sarah E.
Urquiaga, Mariana
Alonso, Carolyn D.
Kelly, Ciaran P.
ANAEROBE, 2020, 61

← 1 2 3 4 5 →